Related Experiment Videos
Inhibitors of endothelin
1Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-400, USA.
Medicinal Research Reviews
|January 1, 1997
Summary
The first endothelin antagonists offer new therapeutic options. Clinical research is actively exploring their broad medical uses and potential benefits.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Development
Background:
- Endothelin antagonists represent a novel class of drugs.
- Selective and nonselective agents are now available.
- Their therapeutic applications are emerging.
Purpose of the Study:
- To explore the clinical potential of endothelin antagonists.
- To identify future therapeutic utilities for these compounds.
Main Methods:
- Clinical trials investigating endothelin antagonists.
- Pharmacological profiling of selective and nonselective agents.
Main Results:
- Early clinical data suggest promising therapeutic roles.
- The full spectrum of benefits is under investigation.
Conclusions:
- Endothelin antagonists hold significant clinical promise.
- Further research will elucidate their manifold therapeutic potentials.